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THE EFFECT OF INTRAVENOUS ZOLEDRONIC ACID
ON GLUCOCORTICOID-INDUCED MULTIPLE
VERTEBRAL FRACTURES IN JUVENILE SYSTEMIC
LUPUS ERYTHEMATOSUS
Sonia Cristina de Magalhães Souza, Claudia Tereza Lobato Borges, Vanda Jorgetti
and Rosa Maria Rodrigues Pereira
SOUZA SC de M et al. The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in
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Glucocorticoids are widely used in the treatment of lupus patients, and adverse effects, which include osteoporosis and
associated fractures, are frequent. Treatment of osteoporosis of young patients should be effective and not harmful to bone
growth and remodeling. Bisphosphonates are drugs that decrease the incidence of bone fractures, but their use in juvenile
patients is still controversial because of their possible side effects on the growing skeleton. However, recently published
studies showed that linear growth continued normally after treatment with these drugs, and there was no excessive suppression
of bone remodeling or mineralization defects. Zoledronic acid is a new intravenous bisphosphonate that has been approved
by the US FDA for use with hypercalcemia of malignancies and might be an effective treatment for postmenopausal
osteoporosis.
The authors report a case of a young girl with systemic lupus who developed multiple vertebral collapses due to
glucocorticoid therapy, and zoledronic acid was used producing significant clinical and densitometric improvement.
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Glucocorticoids (GC), prescribed
because of their immunosuppressive
and anti-inflammatory features, are the
most common cause of secondary os-
teoporosis. It is estimated that 10% of
children may require some form of GC
at some point in their childhood.1 Im-
pairment of childhood growth with an
approximate cortisone dose of 1.5 mg/
kg/day was first described over 40
years ago; osteopenia in children re-
ceiving a prednisolone dose of less
than 0.16 mg/kg/day has also been re-
ported.2,3 The incidence of GC-induced
osteoporosis is approximately 50% in
patients treated for more than 6
months, and it has been estimated that
over 34% of patients on long-term GC
have had fractures.4,5 Skeletal wasting
appears to be both dose and treatment
duration dependent, and the cumula-
tive dose also affects the severity of
bone loss.6 There is a rapid onset of
trabecular bone loss (10% to 20%) as
early as 3 months after initiation of
therapy, followed by a slower rate of
2% per year thereafter. Osteoporotic
vertebral fractures and deformities re-
sult in back pain, limitations in physi-
cal functioning, psychosocial impair-
ment, and a reduced quality of life.7-8
Despite the high prevalence of this ia-
trogenic morbidity associated with
long-term use of glucocorticoid, co-
prescription of therapy for osteoporo-
sis is low, ranging from 5.6% to 14%.9
Bisphosphonates are drugs that in-
hibit osteoclastic bone resorption, in-
creasing bone mineral density and de-
creasing the incidence of fractures.
Oral administration of these drugs
causes esophageal irritation and injury,
and their low bioavailability and low
potency necessitate frequent adminis-
tration on an empty stomach (which
may reduce compliance). Intermittent
intravenous bisphosphonates may be
a way to avoid the problem associated
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with oral administration. Zoledronic
acid is an intravenous bisphosphonate.
On the basis of in vitro studies and ani-
mal models of osteoclast-mediated
bone resorption, this drug is the most
potent biphosphonate among a large
number of other compounds tested.
This drug maintains bone mass in
estrogen-deficient animals without an
adverse effect on mineralization.10 In
postmenopausal women, zoledronic
acid produces an effect on bone turno-
ver and bone density as great as those
achieved with daily oral administra-
tion of other bisphosphonates, with
proven efficacy against fractures with
only an annual infusion.11 Moreover,
it has demonstrated efficacy in the re-
duction of skeletal events in patients
with multiple myeloma, metastatic
breast cancer, prostate cancer, or other
solid tumors and hypercalcemia of ma-
lignancy.
The use of bisphosphonates in ju-
venile patients is still controversial
because of their possible side effects
on the growing skeleton. The authors
searched the Medline and Lilacs
databases for text words, zoledronic
acid, osteoporosis, and children, in the
title, keywords, and abstracts and
could not find another published case
in which the zoledronic acid was used
in a child or an adolescent for any rea-
son.
The authors report a case of a
young girl with systemic lupus who
developed multiple vertebral col-
lapses due to glucocorticoid therapy,
and zoledronic acid was used, produc-
ing significant clinical and
densitometric improvement.
CASE REPORT
A 13-year-old Caucasian girl was
admitted to our hospital from another
medical center 8 months after diagno-
sis of systemic lupus. At presentation,
she had cutaneous vasculitis, polyar-
thritis, pericarditis, and high levels of
anti-DNA antibodies. At that time, she
could not walk or sit and could hardly
move in bed. She had a history of 2
episodes of dorsal pain after rough
movements and could not move be-
cause of the pain. She had been tak-
ing prednisone and azathioprine since
the diagnosis. Calcium, vitamin D,
and calcitonin (200 UI/day nasal) were
initiated after the first episode of dor-
sal pain, which occurred in the fourth
month after the diagnosis (by this time
she had already received a cumulative
dose of prednisone of 8.25 g). On this
occasion, she had vertebral fractures in
T2 and T5 revealed by her first x-ray.
At her admission in our hospital, bio-
chemical markers, dual-energy x-ray
absorptiometry (DXA), new spinal x-
rays, and a bone biopsy were per-
formed. Serum levels of calcium, phos-
phorus, alkaline phosphatase, and
PTH were normal. The DXA showed a
spine (L1 to L4) bone mineral density
(BMD) = 0.444 g/cm2 with a z score =
–4.27, a femoral neck BMD = 0.610
g/cm2, and a whole body BMD =
0.735 g/cm2. Spine x-ray revealed gen-
eralized thoracic and lumbar vertebral
collapse (Figure 1). Bone biopsy per-
formed at the iliac crest, after informed
consent by parent, showed reduction
in the cancellous volume, trabecular
thinning, and disconnections of
trabecula (Figure 2). Tetracycline
labeling was observed only in cortical
bone.
The patient was medicated with
endovenous zoledronic acid (4 mg,
once), since she could not receive oral
Figure 2 – Bone biopsy showed reduction on the cancellous volume, trabecular thinning, and
disconnections of trabecula.
Figure 1 – Spine x-ray revealed generalized
thoracic and lumbar vertebral collapse.
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bisphosphonate because of the high
possibility of developing esophagitis.
A month later, she gradually started
walking again. New bone density
determinations 6 months after
zoledronic acid administration re-
vealed for the lumbar spine (L1-L4) a
BMD = 0.579 g/cm2, z score = –3.18
(an increase of 52%); for the femoral
neck BMD = 0.610 g/cm2 (an increase
of 12.8%); and for whole body BMD
= 0.784 g/cm2, (an increase of 11.2%).
Currently, the patient has an inactive
disease, and she is using a low dose of
prednisone (2.5 mg/day). We are plan-
ning to further reduce the glucocorticoid
and maintain this patient with azathio-
prine and chloroquine. Regarding the
osteoporosis treatment, she is only using
calcium, vitamin D, and the BMD will
be repeated each year. If the BMD re-
mains very low (T score <-2.5) and if she
will need 5 mg/day or more of glucocor-
ticoid for more than 3 months, she will
receive zoledronic acid 4 mg/year or an-
other bisphosphonate (alendronate: 70
mg/week or 10 mg/day, oral) depending
on the availability of these drugs in our
hospital. Because bisphosphonates are
not indicated to be used during preg-
nancy and the long-term side effects of
bisphosphonate use on the fetus are un-
known, we will advise her to avoid preg-
nancy, and we will also try to prescribe
this drug for the shortest time possible.
DISCUSSION
Current studies and clinical obser-
vations suggest that children who re-
quire long-term systemic GC therapy
have a higher incidence of fractures
during their use.12,13 For adults, the
American College of Rheumatology
recommends life style adaptations, sup-
plementation with calcium and vitamin
D, and bisphosphonates in patients re-
ceiving, or initiating therapy with pred-
nisone equivalent of ≥5 mg/day.14 In
the absence of any clear guidelines for
children, it is important to monitor sus-
ceptible patients carefully with review
of bone symptomatology, GC dosage,
nutrition, anthropometry, and pubertal
and bone mineralization status. Chil-
dren at high risk for GC-induced oste-
oporosis and those displaying growth
failure should have serial bone mineral
density assessments. Prevention of GC-
induced growth retardation could be
addressed in a number of cases by a pru-
dent use of GC therapy, improved nu-
trition, and promotion of weight-bear-
ing activities. Calcium and vitamin D
supplementation should always be rec-
ommended.
The bisphosphonates decrease
bone resorption and turnover and re-
duce the incidence of bone fractures,
being recommended for the treatment
and prevention of corticosteroid-in-
duced osteoporosis in adults.14 The use
of bisphosphonates in children and
adolescents is still controversial be-
cause of their possible harmful effects
on the growing skeleton. The role of
antiresorptive drugs (bisphosphonates)
has been mostly studied in the field of
osteogenesis imperfecta where their
use is associated with a reduction in
the frequency of fractures and im-
provement of bone mass and mobil-
ity.15 Published studies in children with
osteogenesis imperfecta have shown
that linear growth continued normally
on treatment, and there was no exces-
sive suppression of bone remodeling
or mineralization defects.16
Our patient had a debilitating con-
dition caused by the vertebral frac-
tures, in which she could not even sit
up in bed to take medications, and the
risk of esophageal irritation and injury
with the use of oral bisphosphonates
was not small. Additionally, the pro-
longed period of immobility was very
detrimental, since it could promote
further fractures. For these reasons, an
intravenous, highly potent
bisphosphonate was prescribed, and
significant clinical and densitometric
improvement was observed. Further
prospective clinical trials should be
carried out to accurately define the ef-
ficacy and safety of this drug in oste-
oporotic juvenile patients.
RESUMO
SOUZA SC de M e col. Efeito do
ácido zoledrônico nas múltiplas
fraturas vertebrais induzidas por
glicocorticóide no lúpus erite-
matoso juvenil. Rev. Hosp. Clín.
Fac. Med. S. Paulo 59(5):302-305,
2004.
Glicocorticóides são fármacos
comumente usados no tratamento de
pacientes lúpicos, porém apresentam
efeitos adversos importantes, princi-
palmente a osteoporose e fraturas. O
tratamento da osteoporose em pacien-
tes jovens deve ser eficaz e não preju-
dicial ao crescimento e remodela-
mento ósseo. Os bisfosfonatos são dro-
gas que reduzem a incidência de fra-
turas, mas seu uso em crianças e ado-
lescentes ainda é controverso, devido
a seus possíveis efeitos adversos no es-
queleto em crescimento. Estudos re-
centemente publicados demonstraram
que o crescimento linear se manteve
normal com o uso de bisfosfonatos,
não havendo supressão excessiva do
remodelamento ósseo ou defeitos de
mineralização. O ácido zoledrônico é
um novo bisfosfonato endovenoso
aprovado pelo FDA para o uso na
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hipercalcemia das neoplasias e parece
ser um tratamento eficaz para a osteo-
porose pós-menopáusica.
Os autores descrevem um caso de
uma adolescente lúpica que desenvol-
veu múltiplas fraturas vertebrais indu-
zidas pelo glicocorticóide e obteve
importante melhora clínica e densito-
métrica após o tratamento com o áci-
do zoledrônico.
UNITERMOS: Osteoporose indu-
zida por glicocorticóide. Osteoporose
juvenil. Ácido zoledrônico. Bisfos-
fonatos.
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